[ad_1] Results of a Phase 3 clinical trial, KRONOS, evaluating AstraZeneca (NYSE: AZN) triplet treatment with PT010 (budesonide / glycopyrronium / formoterol fumarate) compared to dual therapies Aerosphere Bevespi (glycopyrronium fumarate / …
Read More »AstraZeneca's PT010 Offers Therapeutic Benefits in the Study of Advanced COPD – AstraZeneca Group plc (NYSE: AZN)
